Januvia
E468957
Januvia is a prescription medication (sitagliptin) used to help control blood sugar levels in adults with type 2 diabetes.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
DPP-4 inhibitor
ⓘ
antihyperglycemic agent ⓘ brand name drug ⓘ prescription medication ⓘ |
| affects | DPP-4 enzyme ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| canBeUsedAs | monotherapy for type 2 diabetes ⓘ |
| canBeUsedInCombinationWith |
insulin
ⓘ
metformin ⓘ sulfonylureas ⓘ thiazolidinediones ⓘ |
| canCause | hypoglycemia when used with insulin or sulfonylureas ⓘ |
| commonAdverseEffect |
gastrointestinal discomfort
ⓘ
headache ⓘ nasopharyngitis ⓘ upper respiratory tract infection ⓘ |
| contraindication | known hypersensitivity to sitagliptin ⓘ |
| developedBy | Merck & Co. NERFINISHED ⓘ |
| dosageForm | tablet ⓘ |
| doseAdjustmentRequiredIn | renal impairment ⓘ |
| FDAApprovalYear | 2006 ⓘ |
| hasActiveIngredient | sitagliptin phosphate ⓘ |
| hasATCCode | A10BH01 ⓘ |
| hasGenericName | sitagliptin NERFINISHED ⓘ |
| indicatedFor | type 2 diabetes mellitus ⓘ |
| marketedBy | Merck & Co. NERFINISHED ⓘ |
| mechanismOfAction |
decreases hepatic glucose production
ⓘ
increases incretin hormone levels ⓘ increases insulin release in a glucose-dependent manner ⓘ inhibits dipeptidyl peptidase-4 (DPP-4) ⓘ |
| notIndicatedFor |
diabetic ketoacidosis
ⓘ
type 1 diabetes mellitus ⓘ |
| pregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| requires | prescription ⓘ |
| requiresMonitoringOf | renal function ⓘ |
| routeOfAdministration | oral ⓘ |
| seriousAdverseEffect |
acute pancreatitis
ⓘ
hypersensitivity reactions ⓘ severe joint pain ⓘ |
| takenOnceDaily | true ⓘ |
| takenWith | or without food ⓘ |
| targetPopulation | adults with type 2 diabetes ⓘ |
| therapeuticClass | oral antidiabetic drug ⓘ |
| typicalDose | 100 mg once daily in adults with normal renal function ⓘ |
| usedFor |
glycemic control in adults with type 2 diabetes
ⓘ
lowering blood glucose levels ⓘ |
| warning |
risk of hypersensitivity reactions including anaphylaxis
ⓘ
risk of pancreatitis ⓘ risk of severe arthralgia ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.